Seamus Mulligan

Seamus Mulligan (board member) discloses dealings in 2 companies, chiefly Jazz Pharmaceuticals plc and Emergent BioSolutions Inc. We count 109 filings; the first trade dates from 9 March 2012 and the latest from 5 August 2026.

Both buying and selling appear: 13 purchases worth €20.3M, against 74 sales worth €231.0M. Netting one side against the other leaves €210.6M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 18 share grants and 2 option exercises.

The median purchase comes to €1.0M. The 13 purchases reviewed show no overlap with other insiders buying the same stock within a month. Looking at 13 purchases old enough to measure, the stock rose over the following 90 days in 69% of cases; the median change was +5.0%. They describe history only and say nothing certain about the share price ahead.

On 7 August 2026 came the latest disclosure, a share grant in Jazz Pharmaceuticals plc. The last insider purchase was made public on 13 May 2025, 544 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.